International Journal of
Molecular Sciences

MDPI

Article

The Role of Senescence in the Step-by-Step Development of Endometrial Cancer

Artem L. Toropov †, Elizaveta S. Alekseevskaya †, Pavel I. Deryabin and Aleksandra V. Borodkina *

Mechanisms of Cellular Senescence Laboratory, Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky Ave. 4, Saint-Petersburg 194064, Russia; lizalex.otus@gmail.com (E.S.A.)
* Correspondence: borodkina618@gmail.com; Tel.: +7-981-680-14-03
† These authors contributed equally to this work.

Abstract

Endometrial cancer (EC) is one of the most prevalent gynecological malignancies worldwide. Atypical endometrial hyperplasia (AEH) is a premalignant condition with a substantial risk of progression to EC, with the endometrioid subtype (EEC) being the most common. In this study, we investigated the escape-from-senescence concept as a model for the malignant progression from AEH to EEC by bioinformatic analysis of single-cell RNA sequencing data. Unciliated epithelial cells from AEH and EEC tissues exhibited significantly higher levels of senescence compared with those from normal endometrium. Both the proportion of senescent cells (SCs) and their senescence scores remained comparable between hyperplasia and cancer. Despite pronounced genomic instability, SCs in EEC showed no evidence of cell cycle re-entry. RNA velocity analysis revealed no transcriptional trajectories indicating a transition from senescent to non-senescent states in the EEC group. While SCs in AEH and EEC shared similar senescence-associated transcriptional profiles, they demonstrated differences in immunomodulatory activities with enhanced immunosuppressive signaling in the EEC group compared to AEH. Thus, we found no evidence supporting the occurrence of large-scale senescence escape and subsequent malignant conversion of epithelial SCs during EC development. Instead, senescence appears to represent a generalized stress response that persists throughout both premalignant and malignant stages.

Keywords: endometrium; oncogene-induced senescence; escape-from-senescence concept; endometrioid endometrial carcinoma; atypical endometrial hyperplasia; immunosurveillance

Check for updates

Academic Editor: Alfonso Baldi

Received: 9 February 2026
Revised: 26 February 2026
Accepted: 27 February 2026
Published: 28 February 2026

Copyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.

1. Introduction

The endometrium is a highly dynamic tissue that undergoes cyclical breakdown, shedding, repair, and remodeling in response to fluctuating hormone levels throughout a woman's reproductive life. This dynamic nature contributes to the accumulation of somatic mutations in cancer-associated genes, increasing the risk of malignant transformation [1,2]. Indeed, EC, a tumor originating in the inner epithelial lining of the uterus, is the second most common gynecological malignancy diagnosed worldwide after cervical cancer [3]. Among its histological subtypes, EEC is the predominant type, accounting for 70–80% of all EC cases [4,5]. The development of EEC is frequently preceded by AEH, a premalignant condition characterized by abnormal endometrial gland proliferation and cellular atypia, often resulting from prolonged unopposed estrogen exposure [6]. Considerable efforts have

been devoted to elucidating the potential risks and pathways involved in the progression of AEH to EEC to develop more effective strategies for preventing malignancy [6,7].

Senescence is one of the primary cellular defense mechanisms against malignant transformation [8,9]. Indeed, cells exhibiting senescence features are typically found in premalignant lesions, whereas advanced cancer stages are often associated with the loss of these characteristics [8,10,11]. As a fundamental stress response, senescence can be triggered by various stressors, including oncogene overexpression and tumor suppressor downregulation [12,13]. The induction of senescence in response to these stimuli results from irreparable DNA damage, which activates the DNA damage response and leads to irreversible cell cycle arrest [12]. Therefore, cells enter senescence to prevent the accumulation of DNA damage, genomic instability, and subsequent malignant transformation [9].

Despite sustaining damage and undergoing irreversible cell cycle arrest, SCs remain metabolically active and can persist within tissues. Recently, it has been suggested that cells maintaining a senescent state for prolonged periods and acquiring related genomic, transcriptomic, and metabolic alterations can resume proliferation, thereby contributing to cancer progression [14]. This phenomenon was termed the escape-from-senescence concept [14–16]. Notably, escaped cells exhibit a complete resumption of the cell cycle, are invasive, and can generate tumors upon injection into nude mice, thereby recapitulating all major features of cancer cells [14,15,17]. Therefore, escape from senescence can be regarded as a model of cancer progression. In the present study, we investigated the escape-from-senescence concept as a model of EC progression.

2. Results

2.1. Identification of Senescent Epithelial Cells During the Step-by-Step Development of Endometrial Cancer

To elucidate the role of senescence in EC development, we reanalyzed the single-cell RNA sequencing (scRNA-seq) dataset [7] that included samples from normal endometrium, AEH, and EEC (Figures 1A,B and S1A). Subjects in all groups were comparable in age (ranging from 44 to 54 years), and all EEC patients had low-grade tumors (grade 1) [7]. Both AEH and EEC originate from epithelial cells, and the epithelium exhibited a higher co-expression of well-established senescence markers, *CDKN1A* (p21) and *CDKN2A* (p16), compared to other cell types (Figure 1C). Since the unciliated epithelium was identified as the source of EEC in the original study [7], we subsetted unciliated epithelial cells for subsequent senescence analysis.

One of the main challenges in studying senescence using scRNA-seq data is the accurate identification of SCs. In this study, we used six different gene sets to detect SCs in the endometrial epithelium. Four of these gene sets—GO: Cellular Senescence, Reactome: SASP, "Fridman senescence up," and SenMayo—are commonly used to identify SCs across various tissues. However, SCs exhibit high heterogeneity, and their transcriptomic profiles largely depend on their origin, underscoring the need for cell type-specific senescence gene sets. To overcome this obstacle, we also applied the Brosens and Schwartz signatures, which were derived from studies of SCs in the epithelium of the endometrium and the oral cavity, respectively [18,19]. The predictive performance of each gene set was evaluated based on its ability to identify cells expressing both classic senescence markers, *CDKN1A* and *CDKN2A* (Figure 1D–F). Among the gene sets tested, the Brosens signature demonstrated the highest area under the receiver operating characteristic curve (AUC ROC), indicating its superior ability to distinguish SCs from non-SCs in the endometrial epithelium. This result was expected, as the Brosens signature was originally developed to characterize senescent epithelial cells in both normal human endometrium and endometrial assembloids [18].

Six clusters of unciliated epithelial cells were identified (Figure 1G). Compared to the other clusters, the Ep3 cluster exhibited higher enrichment scores for the Brosens signature and various inflammation-related pathways, including inflammatory response, complement activation, interferon-gamma response, and IL6-JAK-STAT3 signaling, alongside lower enrichment scores for gene sets associated with the cell cycle and cell division (Figure 1H). Furthermore, the Ep3 cluster was characterized by increased expression of genes involved in KRAS signaling, which is typically considered one of the principal triggers of oncogene-induced senescence (OIS) [11]. Based on these findings, we identified the Ep3 cluster as senescent. Interestingly, cells in the Ep3 cluster also showed upregulated expression of oncogenic subpopulation markers (Figure S1B), previously identified in the original study [7].




Figure 1. Identification of senescent epithelial cell subpopulation emerging during endometrial carcinoma progression. (**A**,**B**) UMAP plots of endometrial cells colored by (**A**) stages of endometrial pathology and (**B**) cell types. Normal: normal endometrium; AEH: atypical endometrial hyperplasia; EEC: endometrioid endometrial cancer. (**C**) Expression level of senescence marker genes *CDKN1A* and *CDKN2A* in endometrial cells. (**D**) Expression pattern of senescence marker genes *CDKN1A* and *CDKN2A* in unciliated epithelial cells. (**E**) Table comparing the performance of six senescence gene signatures in predicting *CDKN1A*+*CDKN2A*+ endometrial epithelial cells. (**F**) Enrichment scores for the Brosens senescence signature in unciliated epithelial cells. (**G**) UMAP plot of unciliated epithelial cells colored by cell clusters. (**H**) Heatmap showing single-sample gene set enrichment analysis (GSEA) results to characterize the clusters of unciliated epithelial cells using Molecular Signatures Database (MSigDB) hallmark gene set collection. (**I**) Box plot illustrating changes in the proportion of the Ep3 cluster during EEC progression.

Notably, the Ep3 cluster was almost absent in normal endometrial samples but became significantly more pronounced (~20% of cells) in samples obtained from premalignant and malignant endometrium (Figure 1I). The Ep4 and Ep6 clusters were also enriched in the AEH and EEC groups compared to normal endometrium (Figure S1C).

However, unlike Ep3, these clusters were unevenly represented across hyperplasia and cancer samples (Figure S1C) and were therefore associated with donor-to-donor variability rather than a pathogenic process related to malignant transformation. Thus, the results demonstrate that (1) the development of EC is associated with the accumulation of senescent epithelial cells at both premalignant and malignant stages; (2) SCs represent a significant part of the epithelium in both hyperplasia and cancer endometrium samples; and (3) senescence is a common response to malignant transformation in the endometrium, unaffected by sample heterogeneity.

2.2. Characterization of Senescent Epithelial Cells in Endometrial Hyperplasia and Cancer with Focus on the Escape-from-Senescence Concept

The finding that premalignant and malignant endometrial tissues harbor comparable fractions of SCs was unexpected, considering the escape-from-senescence concept as a potential model of EC development. According to this concept, EC progression may occur as follows: in response to a certain level of DNA damage resulting from oncogene activation, normal epithelial cells enter senescence, transitioning to a premalignant state. In case of insufficient DNA repair, gradually acquired genetic alterations lead to the overcoming of the senescence barrier, the emergence of cells with low senescence levels and high genomic instability rates, and, finally, to malignant transformation (Figure 2A). Importantly, escape-from-senescence should also be characterized by escape from proliferation arrest, reacquisition of replication potency, and cell cycle re-entry.




Figure 2. Characterization of senescent epithelial cells from different stages of endometrial pathology. (**A**) Schematic representation illustrating the initial hypothesis that cancer cells originate through an "escape" from senescence. (**B**–**D**) Box plots showing the values of (**B**) senescence, (**C**) genome instability, and (**D**) proliferation scores across epithelial cell clusters and different endometrial pathology stages. The statistical test results for group comparison are provided in Supplementary Materials. (**E**) UMAP plots displaying RNA velocity analysis results for each studied group. Arrows represent embedded velocity vectors.

To further test this concept, we compared SCs across the studied groups using metrics of senescence, genome instability, and replication potency (Figure 2B–D). The median values of Brosens signature enrichment scores in the Ep3 cluster were comparable between groups (Figure 2B). However, a substantial portion of cells in the AEH and EEC groups exhibited significantly elevated senescence levels. Genome instability, evaluated by the integrated copy number variation (CNV) score, increased gradually from normal to EEC samples, as expected (Figure 2C). This elevation in CNV score was observed in all epithelial clusters, including Ep3. The proliferation score was highest in the Ep5 cluster (Figure 2D),

while the Ep3 cluster demonstrated one of the lowest proliferation scores across all studied groups. Therefore, despite pronounced genomic instability, there was no evidence of cell cycle re-entry in SCs derived from EEC samples.

If SCs escape from senescence and give rise to malignant cells, this trajectory would be expected to manifest in transcriptional dynamics. In RNA velocity analysis, the future state of individual cells is predicted by analyzing the ratio of unspliced to spliced mRNA transcripts. However, splicing kinetic analysis did not reveal pronounced trajectories from the senescent cluster to other clusters in the AEH and EEC groups (Figure 2E). The velocity streamlines passing through SCs did not extend beyond the Ep3 cluster boundaries and gradually weakened from normal to EEC samples (Figure 2E).

Thus, we were unable to confirm the dynamic illustrated in Figure 2A and observed in experimental models [11,16] using in vivo data in pathological contexts. The senescence scores and the number of senescent epithelial cells in EEC were similar to those in hyperplasia. In EEC samples, the senescent cluster (1) did not exhibit features indicative of cell cycle re-entry, and (2) did not show velocity vectors directed toward other clusters, contrary to the view that SCs regain replication potential and give rise to malignant cells as proposed by the escape-from-senescence concept.

2.3. Comparative Analysis of Senescent Epithelial Cells in Endometrial Hyperplasia and Cancer Revealed Differences in Immunomodulatory Activity

Considering the substantial proportion of SCs in the epithelium of both AEH and EEC samples, along with growing evidence that SCs play diverse roles in tumorigenesis beyond solely anti-tumor protection [20,21], we performed a comparative analysis of senescent cell expression profiles between the AEH and EEC groups. To do so, pseudobulk differential expression analysis (DEA) with two factors—sample group (AEH versus EEC) and senescence status (non-senescent versus senescent)—was conducted. The interaction model revealed no difference in the senescence effect between the AEH and EEC groups; therefore, the design formula was simplified to an additive model (Figure S2).

For the sample group factor, the products of differentially expressed genes (DEGs) in unciliated epithelium included regulators of Wnt signaling (up in EEC: *DKK4*, *NOTUM*), mediators of cell adhesion and extracellular matrix components (down in EEC: *CDH6*, *THSD7B*, *COL1A2*, *COL3A1*), transcription factors (up: *PROX1*, *TBX18*, *SIM2*; down: *ZFPM2*), and other regulators of cell development and signaling. GSEA showed the activation of Myc, Wnt, and mTORC1 signaling and RNA metabolism, with a suppression of inflammatory and differentiation-related processes in EEC (Figure S2A–C). Thus, the AEH-to-EEC transition is marked by the activation of cell fate-determining pathways along with the loss of epithelial integrity and increased invasive potential.

For the senescence status factor, markedly more DEGs were detected (Figure S2D). Genes upregulated in SCs were involved in epithelial cell structural integrity and adhesion (*KRT* genes, *DSG3*, *CEACAM6*, *SCEL*), lysosomal activity (*CSTA*, *CTSE*, *CSTB*), and inflammatory/immune responses (*SAA1-2*, *LCN2*, *FAM3D*, *CXCL* genes, *IL1RN*, *CASP1*, *CD59*), while downregulated genes were engaged in DNA synthesis and repair (*RRM2*, *EXO1*, *REXO5*, *TOP2A*), cell cycle (*CCNA2*, *CDCA3*, *GTSE1*), and transcription regulation (*ERG*, *ESR1*). The senescence process was associated with the upregulation of inflammatory and immune response pathways, KRAS signaling, and the downregulation of cell division-related pathways (Figure S2E,F).

As noted above, DEA with the interaction term revealed no significant differences in senescence-associated expression patterns between the AEH and EEC groups. The DEGs in SCs from both groups were related to the stage of EC development (Figures 3A and S2G–I). On the one hand, the absence of differences in the senescence

process between the hyperplasia and carcinoma once again indicates the universality of senescence as a cellular response to stress. On the other hand, SCs in these groups were not identical, as they exhibit changes in expression patterns associated with their pathological context. Thus, SCs in the EEC compared with AEH demonstrated the downregulation of inflammation-related pathways, including interferon response, complement activation, and leukocyte proliferation pathways (Figure S2H,I). These changes suggest functional differences in SC activity. Given that SCs can exert both immunostimulatory and immunosuppressive effects [20–22], we hypothesized that the immunomodulatory functions of SCs differ between AEH and EEC. To test this, we analyzed ligand–receptor interactions between senescent epithelial cells and immune cell subtypes (Figure S3).

Firstly, intercellular communication analysis revealed that the Ep3 cluster displayed the strongest outgoing interaction signals among epithelial cell clusters (Figure 3B). SCs most prominently interacted with myeloid cells, and the most substantial differences between AEH and EEC were observed in interactions with macrophages, monocytes, dendritic cells, NK cells, and CD8+ T cells (Figure 3C). Interaction intensity toward lymphoid cells was higher in the precancerous stage, whereas signaling to monocytes and dendritic cells increased as the disease progressed. Importantly, these patterns of intercellular communication were not driven by differences in immune cell abundance across groups (Figure S3G). The top ligand–receptor pairs showing the largest AEH-EEC differences in outgoing interaction intensity from SCs to the immune cells listed above are presented in Figure 3D–H.

One of the ligands markedly upregulated in EEC SCs was Annexin A1 (ANXA1), an immunomodulatory protein that binds to FPR receptors on myeloid cells (Figure 3D–F). ANXA1 signaling via FPR2 promotes macrophage polarization toward an anti-inflammatory M2 phenotype and, consequently, tumor growth [23]. A similar effect was described for the MDK-LRP1 interaction [24], another pair enriched in EEC. In contrast, the SCs in AEH exhibited stronger interactions with macrophages and monocytes via the complement component C3, a protein of acute inflammatory response (Figure 3D,E).

The SCs in AEH demonstrated an increased intensity of interactions with NK and CD8+ cells (Figure 3C). For NK cells, the top ligand–receptor pairs that predominated in AEH included PLXNB1-SEMA4D (Figure 3G). The modulation of NK cell function via the SEMA4D receptor may lead to both the stimulation of cytotoxicity [25] and immunosuppression in cancer [26]. For CD8+ T cells, precancerous SCs displayed enhanced interaction via EFNAs and CXCL10 chemokine (Figure 3H). EFNA family proteins are associated with immune cell infiltration and tumor progression [27,28], while the CXCL10-CXCR3 axis is essential for CD8+ T cell recruitment and activation [29].

Overall, these data suggest (1) a stronger interaction between senescent and myeloid cells in the EEC group, along with the immunosuppressive nature of this interaction, and (2) a more intense interaction between senescent and lymphoid cells in the AEH group that exhibits both immunostimulatory and immunosuppressive effects. The shift in immunomodulatory activities of SCs in the EEC group was mediated by both the downregulation of immunostimulatory signals, including pro-inflammatory cytokines and immune recruitment molecules, and the upregulation of immune evasion-related and immunosuppressive protein expression (Figure S3H).




Figure 3. Characteristics of interactions between senescent and immune cells at different stages of endometrial carcinoma development. (**A**) Volcano plot of differentially expressed genes between senescent epithelial cells from AEH and EEC groups. Gray dashed lines indicate the significance thresholds used: 0.05 for adjusted *p*-values (padj) and 1 (absolute value) for Log2 fold change (Log2FC). (**B**) Interaction strength of incoming and outgoing signals for different epithelial cell clusters. (**C**) Bar chart showing the overall intensity of signals outcoming from the senescent cell cluster to immune cells at the hyperplasia (AEH) and carcinoma (EEC) stages. (**D**–**H**) Top ligand–receptor pairs with differing outcoming interaction intensity from SCs at the AEH and EEC stages to (**D**) macrophages, (**E**) monocytes, (**F**) dendritic cells, (**G**) NK cells, and (**H**) CD8+ T lymphocytes.

2.4. Validation of the Emergence of Senescent Epithelial Cells in EEC on Additional Datasets

To validate our findings, we analyzed additional data spanning different stages of EC progression. The GSE39099 microarray dataset includes samples of normal, AEH, and EEC endometrium, similar to the main scRNA-seq dataset, and also covers early and advanced EEC stages. Since the Brosens signature is an epithelium-specific senescence gene set (Figure 4A), we were able to use this bulk gene expression data to verify our previous findings. As shown in Figure 4B, the enrichment score of the Brosens signature was increased in AEH and EEC samples compared to normal endometrium and, furthermore, positively correlated with EEC severity.




Figure 4. Identification of a senescent epithelial cell subpopulation in additional endometrial carcinoma datasets. (**A**) Epithelial cells are most enriched with Brosens senescence signature scores. (**B**) Single-sample GSEA results for Brosens senescence signature in microarray dataset GSE39099 of gene expression in the different stages of endometrial cancer. (**C**,**D**) UMAP plots of endometrial epithelial cells from the Guo Y. et al., 2021 dataset [30] colored by (**C**) their association with EEC samples and (**D**) cell types. (**E**) Epithelial cells from the Guo Y. et al., 2021 dataset [30] are the cell type most enriched with senescence and genome instability scores. (**F**–**H**) UMAP plots of unciliated epithelial cells form the Guo Y. et al., 2021 dataset [30] colored by (**F**) samples, (**G**) enrichment scores for the Brosens senescence signature, and (**H**) epithelium cell clusters. (**I**) Box plots showing the values of senescence, genome instability, and proliferation scores across epithelial cell clusters from the validation dataset. (**J**) UMAP plot displaying RNA velocity analysis results for the validation dataset. Arrows represent embedded velocity vectors. (**K**) Interaction strength of incoming and outgoing signals for different epithelial cell clusters from the validation dataset. (**L**) Dot plot showing the top 15 ligand–receptor interactions outcoming from the senescent cluster in the validation dataset.

Additionally, we confirmed our findings using an independent scRNA-seq dataset [30], which included five EEC samples (Figures 4C,D and S4). Similarly to the primary dataset, the epithelial cells exhibited elevated senescence score and markedly higher levels of genomic instability relative to other endometrium cell types (Figure 4E). Analysis of unciliated epithelial cells revealed seven clusters, with Ep2 identified as senescent (Figure 4F–H). Similarly to the SCs in the main dataset, the Ep2 cluster included cells from all studied samples, supporting the universality of the senescence process (Figure 4F). The CNV score was comparable across clusters, and SCs showed no signs of escaping proliferative arrest (Figure 4I). RNA velocity analysis confirmed the absence of trajectories from senescent to non-senescent clusters (Figure 4J). Intercellular communication analysis mirrored prior results: the senescent cluster exhibited the highest outgoing interaction intensity, primarily with myeloid cells (Figure 4K,L). Among the top ligand–receptor pairs involved in senescent–myeloid cell interactions, the ANXA1-FPR1/FPR2/FPR3 and MDK-LRP1 pairs were present (Figure 4L).

To summarize, we found no evidence of senescence escape during EC progression on an additional dataset with samples representing the step-by-step development of EC. Furthermore, the senescence score increased as the disease progressed. The subpopulation of SCs was also revealed in the independent scRNA-seq dataset with EEC samples. This subpopulation was represented by a significant fraction of unciliated epithelial cells from each studied sample and demonstrated no sign of cell cycle re-entry together with a high activity of interactions with immune cells.

3. Discussion

In this study, we examined the validity of the escape-from-senescence concept as a potential pathway for EC development. Cellular senescence, initially described in the context of replicative lifespan limits due to telomere shortening, is now considered a common response to various forms of stress, including genomic damage, oxidative stress, and oncogenic signaling [31–33]. Along with the other forms of senescence, OIS—activated by oncogenes such as Ras, Raf, and Akt, or by the loss of tumor suppressors such as PTEN [20,33]—serves as a barrier to tumorigenesis by halting the proliferation of potentially malignant cells. Although senescence arrest was long considered irreversible, recent studies have demonstrated that, under certain conditions, SCs can escape OIS, regain proliferative potential, and become a source of malignancy [11,14,16].

Based on this body of evidence, we proposed that the progression of AEH to EEC may be driven by cells that escape from OIS. Initially, cells entering senescence in response to genetic alterations during AEH should prevent further malignant transformation. However, if AEH remains undiagnosed and untreated, SCs harboring genetic alterations may escape senescence and re-enter the cell cycle, increasing the risk of progression from AEH to EEC. In line with this, we observed that the endometrium from AEH patients exhibited significantly elevated levels of senescence in unciliated epithelium compared to normal endometrium. Unexpectedly, the endometrium from EEC patients also displayed a pronounced fraction of SCs comparable to that observed at the AEH stage. The observed absence of senescence decrease in malignant endometrium compared to premalignant tissue challenges the escape-from-senescence concept as a model for EC development. Indeed, despite increasing genomic instability, SCs from EEC samples did not demonstrate a reduction in senescent levels accompanied by the restoration of proliferative potential. An alternative to reacquiring proliferative potency through escape-from-senescence might be the phenomenon of senescent-marker positive cancer cells, in which already malignant cells paradoxically express senescence markers together with the high proliferative rate [34]. We did not find the presence of such dual-phenotype cells in the EEC group as well. More-

over, senescent-associated expression patterns were similar in AEH and EEC. The most pronounced differences between senescent epithelial cells in endometrial hyperplasia and cancer were found in their immunomodulatory activity.

Growing evidence suggests that SCs influence tumorigenesis through the senescence-associated secretory phenotype (SASP), exhibiting both tumor-suppressive and tumor-promoting effects [20,21]. SASP is one of the key features of SCs, representing a wide range of secreted factors, including pro-inflammatory cytokines, chemokines, proteases (such as matrix-remodeling enzymes and plasminogen activators), growth factors, etc. [35,36]. On the one hand, SASP components may produce a pro-inflammatory environment and play a key role in recruiting immune cells, thereby inhibiting cancer progression [20,21,37–39]. On the other hand, SASP components can directly or indirectly promote tumor cell growth, invasion, and metastasis; facilitate tumor vascularization; and create an immunosuppressive microenvironment [20–22,37,38,40]. We observed that SCs in EEC exhibited enhanced immunosuppressive activity compared with those in AEH. In light of these findings, SCs in AEH provide anti-tumor protection through the proliferation arrest of cells harboring genetic alterations, as well as by secreting SASP, which is capable of facilitating immunosurveillance. However, the prolonged persistence of SCs might shift their role toward tumor promotion, primarily through altered immune interactions.

4. Materials and Methods

4.1. Gene Expression Data

scRNA-seq data were obtained from the publicly available dataset under accession number SRP349751. This dataset included endometrial tissue samples from donors with normal endometrium, AEH, and EEC [7]. For validation, we used (1) the GSE39099 microarray dataset containing samples from different stages of EC development, and (2) the PRJNA650549 scRNA-seq dataset, which includes five EEC samples [30].

4.2. Data Preprocessing

Raw reads were processed using Cell Ranger software (v. 7.2.0; https://10xgenomics.com/support/software/cell-ranger (accessed on 26 February 2026)) to map on the reference genome (GRCh38/hg38; refdata-gex-GRCh38-2020-A) and generate gene expression matrices. The matrices were then imported into the R environment (v. 4.4.0) using the 'Read10X' function from the Seurat package (v. 5.1.0; https://github.com/satijalab/Seurat (accessed on 26 February 2026)). Cells with fewer than 800 unique molecular identifiers, more than 20% mitochondrial transcripts, or gene numbers outside the range of 600–7000 were removed. To control the presence of doublet cells, the DoubletFinder tool was used (v. 2.0.4; https://github.com/chris-mcginnis-ucsf/DoubletFinder (accessed on 26 February 2026)). After filtering, the data were preprocessed using the standard Seurat pipeline, and the Harmony method was applied for data integration and batch-effect correction (v. 1.2.0; https://github.com/immunogenomics/harmony (accessed on 26 February 2026)).

4.3. Identification of Senescent Epithelial Cells

Cells were manually annotated based on the expression of canonical marker genes, as well as markers used in the original studies [7,30].

To identify the most relevant gene signature characterizing senescent endometrial epithelial cells, six gene sets were compared: the Brosens signature [18], the Schwartz signature [19], SenMayo, "Fridman senescence up", GO: Cellular Senescence, and Reactome: SASP. The latter four are curated gene sets from the MSigDB collection, with systematic names M45803, M9143, M11558, and M27187, respectively. The Brosens signature, derived from endometrial epithelial cells during decidualization, comprises 88 genes with a log2

fold change > 0.5 and ≥10% increase in the fraction of cells expressing these genes in the EpS5 (senescent) cluster compared to EpS4 (differentiated). The Schwartz signature includes the top 100 upregulated genes ($p < 0.01$) in oral epithelial cells at late versus early passages. Gene set enrichment scores were calculated using the UCell package (v. 2.8.0; https://github.com/carmonalab/UCell (accessed on 26 February 2026)).

The predictive performance of the listed gene sets was evaluated based on their ability to identify cells expressing *CDKN1A* and *CDKN2A* genes. Expression values for *CDKN1A* and *CDKN2A* were first imputed using the MAGIC package (v. 2.0.3; https://github.com/KrishnaswamyLab/MAGIC (accessed on 26 February 2026)). Cells with standardized expression values above zero for both genes were classified as senescent. The ability of each gene signature to distinguish SCs from non-SCs was assessed using a logistic regression model and by calculating AUC ROC values.

4.4. Data Analysis

To assess functional pathway differences between epithelial cell clusters, single-sample GSEA was performed using a non-parametric ssGSEA method from the GSVA package (v. 2.0.5; https://github.com/rcastelo/GSVA (accessed on 26 February 2026)). Similarly, single-sample GSEA was applied to the GSE39099 dataset to determine the Brosens signature enrichment score.

Information on large-scale chromosomal duplications and deletions was obtained from raw gene expression values using the InferCNV package (v. 1.23.0; https://github.com/broadinstitute/inferCNV (accessed on 26 February 2026)). Epithelial cells from normal endometrium samples in the main scRNA-seq dataset and non-epithelial cells in the validation scRNA-seq dataset were used as reference data for CNV analysis. To derive a CNV metric at the single-cell level, we calculated the CNV score as the sum of squared gene state ratings from the zero-centered HMM prediction matrix, normalized by the number of genes used in the analysis.

The proliferative score was estimated as the UCell enrichment score of Seurat's cell cycle gene set, which includes genes associated with the S and G2M phases (https://satijalab.org/seurat/reference/cc.genes.updated.2019 (accessed on 26 February 2026)).

RNA velocity analysis was conducted using the dynamical model with default parameters from the scVelo package (v. 0.3.3; https://scvelo.readthedocs.io/en/stable/ (accessed on 26 February 2026)). Input loom files containing quantification matrices of unspliced and spliced transcripts were generated from Cell Ranger output BAM files using the velocyto package (v. 0.17.17; https://velocyto.org (accessed on 26 February 2026)).

Two-factor DEA for the pseudobulk expression matrix was performed using the DESeq2 package (v. 1.44.0; https://github.com/thelovelab/DESeq2 (accessed on 26 February 2026)). GSEA of the DEA results was conducted using the fast GSEA algorithm from the fgsea package (v. 1.30.0; https://github.com/ctlab/fgsea (accessed on 26 February 2026)).

To identify immune cell subtypes interacting with SCs, we conducted a cell–cell communication analysis using the CommPath package (v. 1.0.0, https://github.com/yingyonghui/CommPath (accessed on 26 February 2026)).

For pairwise comparisons between groups, statistical analysis was performed using a two-tailed Mann–Whitney test with Bonferroni correction via the rstatix package (v. 0.7.2; https://rpkgs.datanovia.com/rstatix (accessed on 26 February 2026)).

5. Conclusions

To summarize, we have demonstrated that the large-scale escape-from-senescence event does not depict the malignant progression from AEH to EEC. On the contrary, senescence represents a nonspecific stress reaction that occurs at each stage of EC development, preventing

the malignant transformation of hyperplastic endometrium, while potentially promoting tumor progression in transformed tissue through altered immunomodulatory activity.

Limitations: One of the primary challenges in studying senescence using scRNA-seq data is the accurate identification of SCs. Our definition of senescence is based on a transcriptomic senescence-related signature and the results of GSEA. Although we use the "SCs" term for convenience, the Ep3 cluster should be interpreted more precisely as "cells with high senescence-associated transcriptional scores." Additionally, while our results argue against a large-scale escape-from-senescence event during EC progression, the single-cell data used and bioinformatics approaches employed may not capture rare, transient, or early escape events that occurred prior to sample collection.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms27052309/s1.

Author Contributions: Conceptualization, A.V.B.; methodology, P.I.D.; software, P.I.D., A.L.T. and E.S.A.; formal analysis, A.L.T. and E.S.A.; investigation, A.L.T. and E.S.A.; data curation, A.L.T. and E.S.A.; writing—original draft preparation, A.V.B.; writing—review and editing, all authors; visualization, A.L.T. and E.S.A.; project administration, A.V.B.; funding acquisition, A.V.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Russian Science Foundation, grant number 24-74-10002, https://rscf.ru/project/24-74-10002/ (accessed on 26 February 2026).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data used in this study are available in the Sequence Read Archive (SRA) repository or the Gene Expression Omnibus (GEO) database under the indicated accession numbers.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

AEH	Atypical endometrial hyperplasia
AUC ROC	Area under the receiver operating characteristic curve
CNV	Copy number variation
EC	Endometrial cancer
EEC	Endometrioid endometrial cancer
DEA	Differential expression analysis
DEG	Differentially expressed gene
GSEA	Gene set enrichment analysis
MSigDB	Molecular Signatures Database
NK	Natural killer
OIS	Oncogene-induced senescence
SASP	Senescence-associated secretory phenotype
SC	Senescent cell
scRNA-seq	Single-cell RNA sequencing

References

1. Moore, L.; Leongamornlert, D.; Coorens, T.H.H.; Sanders, M.A.; Ellis, P.; Dentro, S.C.; Dawson, K.J.; Butler, T.; Rahbari, R.; Mitchell, T.J.; et al. The mutational landscape of normal human endometrial epithelium. *Nature* **2020**, *580*, 640–646. [CrossRef]
2. Yamaguchi, M.; Nakaoka, H.; Suda, K.; Yoshihara, K.; Ishiguro, T.; Yachida, N.; Saito, K.; Ueda, H.; Sugino, K.; Mori, Y.; et al. Spatiotemporal dynamics of clonal selection and diversification in normal endometrial epithelium. *Nat. Commun.* **2022**, *13*, 943. [CrossRef] [PubMed]
3. Makker, V.; MacKay, H.; Ray-Coquard, I.; Levine, D.A.; Westin, S.N.; Aoki, D.; Oaknin, A. Endometrial cancer. *Nat. Rev. Dis. Primers* **2021**, *7*, 88. [CrossRef] [PubMed]
4. Soslow, R.A.; Tornos, C.; Park, K.J.; Malpica, A.; Matias-Guiu, X.; Oliva, E.; Parkash, V.; Carlson, J.; McCluggage, W.G.; Gilks, C.B. Endometrial carcinoma diagnosis: Use of FIGO grading and genomic subcategories in clinical practice: Recommendations of the International Society of Gynecological Pathologists. *Int. J. Gynecol. Pathol.* **2019**, *38*, S64–S74. [CrossRef] [PubMed]
5. González-Martínez, S.; Pérez-Mies, B.; Cortés, J.; Palacios, J. Single-cell RNA sequencing in endometrial cancer: Exploring the epithelial cells and the microenvironment landscape. *Front. Immunol.* **2024**, *15*, 1425212. [CrossRef]
6. Chou, A.J.; Bing, R.S.; Ding, D.C. Endometrial atypical hyperplasia and risk of endometrial cancer. *Diagnostics* **2024**, *14*, 2471. [CrossRef]
7. Ren, X.; Liang, J.; Zhang, Y.; Jiang, N.; Xu, Y.; Qiu, M.; Wang, Y.; Zhao, B.; Chen, X. Single-cell transcriptomic analysis highlights origin and pathological process of human endometrioid endometrial carcinoma. *Nat. Commun.* **2022**, *13*, 6300. [CrossRef]
8. Collado, M.; Serrano, M. Senescence in tumours: Evidence from mice and humans. *Nat. Rev. Cancer* **2010**, *10*, 51–57. [CrossRef]
9. Wang, L.; Lankhorst, L.; Bernards, R. Exploiting senescence for the treatment of cancer. *Nat. Rev. Cancer* **2022**, *22*, 340–355. [CrossRef]
10. Saab, R. Senescence and pre-malignancy: How do tumors progress? *Semin. Cancer Biol.* **2011**, *21*, 385–391. [CrossRef]
11. Martínez-Zamudio, R.I.; Stefa, A.; Nabuco Leva Ferreira Freitas, J.A.; Vasilopoulos, T.; Simpson, M.; Doré, G.; Roux, P.F.; Galan, M.A.; Chokshi, R.J.; Bischof, O.; et al. Escape from oncogene-induced senescence is controlled by POU2F2 and memorized by chromatin scars. *Cell Genom.* **2023**, *3*, 100293. [CrossRef] [PubMed]
12. Hernandez-Segura, A.; Nehme, J.; Demaria, M. Hallmarks of cellular senescence. *Trends Cell Biol.* **2018**, *28*, 436–453. [CrossRef]
13. Zhu, H.; Blake, S.; Kusuma, F.K.; Pearson, R.B.; Kang, J.; Chan, K.T. Oncogene-induced senescence: From biology to therapy. *Mech. Ageing Dev.* **2020**, *187*, 111229. [CrossRef]
14. Evangelou, K.; Belogiannis, K.; Papaspyropoulos, A.; Petty, R.; Gorgoulis, V.G. Escape from senescence: Molecular basis and therapeutic ramifications. *J. Pathol.* **2023**, *260*, 649–665. [CrossRef]
15. Gorgoulis, V.; Adams, P.D.; Alimonti, A.; Bennett, D.C.; Bischof, O.; Bishop, C.; Campisi, J.; Collado, M.; Evangelou, K.; Ferbeyre, G.; et al. Cellular senescence: Defining a path forward. *Cell* **2019**, *179*, 813–827. [CrossRef]
16. Zampetidis, C.P.; Galanos, P.; Angelopoulou, A.; Zhu, Y.; Polyzou, A.; Karamitros, T.; Kotsinas, A.; Lagopati, N.; Mourkioti, I.; Mirzazadeh, R.; et al. A recurrent chromosomal inversion suffices for driving escape from oncogene-induced senescence via subTAD reorganization. *Mol. Cell* **2021**, *81*, 4907–4923.e8. [CrossRef]
17. Komseli, E.S.; Pateras, I.S.; Krejsgaard, T.; Stawiski, K.; Rizou, S.V.; Polyzos, A.; Roumelioti, F.M.; Chiourea, M.; Mourkioti, I.; Paparouna, E.; et al. A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence. *BMC Genom.* **2018**, *19*, 37. [CrossRef] [PubMed]
18. Rawlings, T.M.; Makwana, K.; Taylor, D.M.; Molè, M.A.; Fishwick, K.J.; Tryfonos, M.; Odendaal, J.; Hawkes, A.; Zernicka-Goetz, M.; Hartshorne, G.M.; et al. Modelling the impact of decidual senescence on embryo implantation in human endometrial assembloids. *eLife* **2021**, *10*, e69603. [CrossRef]
19. Schwartz, R.E.; Shokhirev, M.N.; Andrade, L.R.; Gutkind, J.S.; Iglesias-Bartolome, R.; Shadel, G.S. Insights into epithelial cell senescence from transcriptome and secretome analysis of human oral keratinocytes. *Aging* **2021**, *13*, 4747–4777. [CrossRef] [PubMed]
20. Yang, J.; Liu, M.; Hong, D.; Zeng, M.; Zhang, X. The paradoxical role of cellular senescence in cancer. *Front. Cell Dev. Biol.* **2021**, *9*, 722205. [CrossRef]
21. Zhou, L.; Ma, B.; Ruscetti, M. Cellular senescence offers distinct immunological vulnerabilities in cancer. *Trends Cancer* **2025**, *11*, 334–350. [CrossRef]
22. Fan, G.; Xie, T.; Tan, Q.; Lou, N.; Wang, S.; Han, X.; Shi, Y. An immunosuppressive subtype of senescent tumor cells predicted worse immunotherapy response in lung adenocarcinoma. *iScience* **2023**, *26*, 107894. [CrossRef]
23. Moraes, L.A.; Kar, S.; Foo, S.L.; Gu, T.; Toh, Y.Q.; Ampomah, P.B.; Sachaphibulkij, K.; Yap, G.; Zharkova, O.; Lukman, H.M.; et al. Annexin-A1 enhances breast cancer growth and migration by promoting alternative macrophage polarization in the tumour microenvironment. *Sci. Rep.* **2017**, *7*, 17925. [CrossRef]
24. Shi, N.; Chen, S.; Wang, D.; Wu, T.; Zhang, N.; Chen, M.; Ding, X. MDK promotes M2 macrophage polarization to remodel the tumour microenvironment in clear cell renal cell carcinoma. *Sci. Rep.* **2024**, *14*, 18254. [CrossRef] [PubMed]

25. Mizrahi, S.; Markel, G.; Porgador, A.; Bushkin, Y.; Mandelboim, O. CD100 on NK cells enhance IFNγ secretion and killing of target cells expressing CD72. *PLoS ONE* **2007**, *2*, e818. [CrossRef] [PubMed]
26. Xuan, Z.; Zhang, Y.; Li, D.; Wang, K.; Huang, P.; Shi, J. PLXNB1/SEMA4D signals mediate interactions between malignant epithelial and immune cells to promote colorectal cancer liver metastasis. *J. Cell Mol. Med.* **2024**, *28*, e70142. [CrossRef] [PubMed]
27. Hao, Y.P.; Wang, W.Y.; Qiao, Q.; Li, G. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma. *Medicine* **2021**, *100*, e26188. [CrossRef]
28. Li, Y.C.; Zhang, L.; Wang, Y.T.; Hu, H.; Zhang, Z.Y.; Nie, Q.Q.; Zuo, C.J. Role of EFNAs in shaping the tumor immune microenvironment and their impact on pancreatic adenocarcinoma prognosis. *Cancer Manag. Res.* **2025**, *17*, 693–712. [CrossRef]
29. Christensen, J.E.; de Lemos, C.; Moos, T.; Christensen, J.P.; Thomsen, A.R. CXCL10 is the key ligand for CXCR3 on $CD8^+$ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. *J. Immunol.* **2006**, *176*, 4235–4243. [CrossRef]
30. Guo, Y.E.; Li, Y.; Cai, B.; He, Q.; Chen, G.; Wang, M.; Wang, K.; Wan, X.; Yan, Q. Phenotyping of immune and endometrial epithelial cells in endometrial carcinomas revealed by single-cell RNA sequencing. *Aging* **2021**, *13*, 6565–6591. [CrossRef]
31. d'Adda di Fagagna, F. Living on a break: Cellular senescence as a DNA-damage response. *Nat. Rev. Cancer* **2008**, *8*, 512–522. [CrossRef]
32. Campisi, J. Aging, cellular senescence, and cancer. *Annu. Rev. Physiol.* **2013**, *75*, 685–705. [CrossRef]
33. Gergues, M.; Bari, R.; Koppisetti, S.; Gosiewska, A.; Kang, L.; Hariri, R.J. Senescence, NK cells, and cancer: Navigating the crossroads of aging and disease. *Front. Immunol.* **2025**, *16*, 1565278. [CrossRef]
34. O'Sullivan, E.A.; Wallis, R.; Mossa, F.; Bishop, C.L. The paradox of senescent-marker positive cancer cells: Challenges and opportunities. *npj Aging* **2024**, *10*, 41. [CrossRef]
35. Borodkina, A.V.; Deryabin, P.I.; Giukova, A.A.; Nikolsky, N.N. "Social life" of senescent cells: What is SASP and why study it? *Acta Naturae* **2018**, *10*, 4–14. [CrossRef] [PubMed]
36. Yue, Z.; Nie, L.; Zhao, P.; Ji, N.; Liao, G.; Wang, Q. Senescence-associated secretory phenotype and its impact on oral immune homeostasis. *Front. Immunol.* **2022**, *13*, 1019313. [CrossRef]
37. Lasry, A.; Ben-Neriah, Y. Senescence-associated inflammatory responses: Aging and cancer perspectives. *Trends Immunol.* **2015**, *36*, 217–228. [CrossRef] [PubMed]
38. Capece, D.; Verzella, D.; Tessitore, A.; Alesse, E.; Capalbo, C.; Zazzeroni, F. Cancer secretome and inflammation: The bright and the dark sides of NF-κB. *Semin. Cell Dev. Biol.* **2018**, *78*, 51–61. [CrossRef]
39. Alessio, N.; Acar, M.B.; Squillaro, T.; Aprile, D.; Ayaz-Güner, Ş.; Di Bernardo, G.; Peluso, G.; Özcan, S.; Galderisi, U. Progression of irradiated mesenchymal stromal cells from early to late senescence: Changes in SASP composition and anti-tumour properties. *Cell Prolif.* **2023**, *56*, e13401. [CrossRef] [PubMed]
40. Davalos, A.R.; Coppe, J.P.; Campisi, J.; Desprez, P.Y. Senescent cells as a source of inflammatory factors for tumor progression. *Cancer Metastasis Rev.* **2010**, *29*, 273–283. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.